“…The sensitivity of all the four cells to 5-FU also varied according to cell types, particularly with CL-6 cell (IC(50 )= 757 micromolar). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…BACKGROUND: XELOX (capecitabine + oxaliplatin) and FOLFOX 4 (5-FU + folinic acid + oxaliplatin) have shown similar improvements in survival in patients with metastatic colorectal cancer (MCRC). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Two eukaryotic DNA-expression-plasmids were used to transfect the mammalian cell line MTH53A applying six different transfection protocols: conventional transfection reagent (FuGENE HD, FHD), FHD in combination with two different sizes of stabilizer-free laser-generated AuNPs (PLAL-AuNPs_S1,_S2), FHD and commercially available AuNPs (Plano-AuNP), and two magnetic transfection protocols. 24 h post transfection efficiency of each protocol was analysed using fluorescence microscopy and GFP-based flow cytometry. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Fit MCRC patients <75 years were consecutively treated with FIr-B/FOx regimen: weekly 12-h timed flat-infusion/5-fluorouracil (TFI 5-FU) 900 mg/m(2), days 1, 2, 8, 9, 15, 16, 22 and 23; irinotecan (CPT-11) 160 mg/m(2 )plus BEV 5 mg/kg, days 1, 15; oxaliplatin (OXP) 80 mg/m(2), days 8, 22; every 4 weeks. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In contrast, 36 patients who declined the adjuvant bi-weekly GEM chemotherapy underwent traditional adjuvant 5FU-based chemotherapy (Group B). Careful periodical follow-ups for side effects of GEM and disease recurrence, and assessment of patients’ QOL using the EORTC QOL questionnaire (QLQ-C30) and pancreatic cancer-specific supplemental module (QLQ-PAN26) were performed. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Patients were treated with 85 mg/m(2) of oxaliplatin as a 2-h infusion at day 1 plus 20 mg/m(2) of leucovorin over 10 min, followed by 5-FU bolus 400 mg/m(2) and 22-h continuous infusion of 600 mg/m(2) at days 1-2. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Additionally, 56 gastric cancer patients treated with a modified FOLFOX regimen(biweekly oxaliplatin plus 5-FU and folinic acid) were retrospectively analyzed to further evaluate the prognostic and predictive impact of SULF2 methylation in gastric cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The combined chemotherapy consisted of gemcitabine 1 g/m(2) (30 min), 5-FU 750 mg/m(2) (24 h), folinic acid 200 mg/m(2) (30 min), and Cisplatin 30 mg/m(2) (90 min) on day 1 and 8; q3w for the first 12 weeks (GFFC) followed by gemcitabine alone in patients without cancer progression. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: NF-κB reporter cells were established and treated with 5-fluorouracil (5-FU, DNA/RNA damaging), oxaliplatin (DNA damaging), camptothecin (CTP, topoisomerase inhibitor), phleomycin (radiomimetic), or erlotinib (EGFR inhibitor). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Human CRC HCT-116 cells were implanted in BALB/c nude mice; mice with xenografted tumors were randomly administrated vehicle (control), 20, 40, or 80 mg/mL VB, or 1 mg/mL fluorouracil (5-FU). HIPK2, p53, Bax, and Bcl-2 expression in these tumors were determined by IHC. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Combination of 1 μM cisplatin, 5-FU, paclitaxel, gemcitabine, or tamoxifen with OP dosages ≥300 μg/mL significantly reduced cell viability at 24, 48, and 72 hours when compared to the chemodrug alone. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…On univariate analysis, age (p = 0.0008), the DFH (Docetaxel/5-FU/Hydroxyurea) chemotherapy regimen (p = .042) and b.i.d treatment (P = 0.040) (used in limited cases on protocol) predicted need for enteral feeding. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…METHODS: Major eligibility criteria were confirmed adenocarcinoma diagnosis; age >20 years; Eastern Cooperative Oncology Group performance status, 0–2; and progression after administration/intolerance of/to approved drugs for mCRC. (5-FU, oxaliplatin, irinotecan, Bev, and anti-EGFR antibody, if KRAS wild-type). …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In the patients aged under 70, significant differences in 4-year overall survival (OS) were noted between UFUR (oral tegafur-uracil plus leucovorin) groups and FOLFOX (5-FU plus oxaliplatin) [65.6% versus (vs) 89.8%, relative risk (RR) 3.780, 95% confidence interval (CI) 1.263–11.315, P = 0.017]. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…In conclusion, Older CRC patients had equal safety of surgery as younger patients, except rectal cancer patients aged ≥80 years that had a higher mortality. Adjuvant 5FU-based chemotherapy did not benefit older CRC patient, while neoadjuvant radiotherapy improved the prognosis of older patients with stage III rectal cancer.…”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…DISCUSSION: In LARC, a neoadjuvant chemotherapy regimen - if feasible, effective and tolerable would be suitable for testing as the novel arm against the current standards of short course preoperative radiotherapy (SCPRT) and/or fluorouracil (5FU)-based CRT in a future randomised phase III trial. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Outcomes are assessed on 4 time-points by a treatment blinded tester: eligibility assessment at baseline (BL) 2–4 days prior to intervention, pre-intervention assessment (T0), post-intervention assessment (T1), and at 4 weeks follow-up (FU). At BL, an additional healthy control group (n = 20) will be assessed to allow cross-sectional comparison with symptom-free participants. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…The data obtained with the DocOx protocol compare well with other second line protocols such as OFF (oxaliplatin, 5-FU, leucovorin). The DocOx regimen could be an interesting option for patients who received gemcitabine as first line treatment for metastatic pancreatic cancer. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…Further analysis revealed a lower rate of non-synonymous (d(N)) than synonymous (d(S)) mutations, suggesting negative (purifying) selection of PkRAP-1. Tajima’s D test and Fu and Li’s D test values were not significant. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso

“…At stage II–III, there was no significant correlation between HER2 overexpression and 5FU/FA response. A higher proportion of HER2‐overexpressing cases experienced recurrence, but the difference was not significant. …”
Enlace del recurso
Enlace del recurso
Enlace del recurso